All patient guidesSemua panduan pasien返回全部指南
July 14, 2026 Patient guidePanduan pasien就医指南

China’s Gene Editing and Stem Cell Therapy Landscape in 2026: What International Patients Need to KnowChina’s Gene Editing and Stem Cell Therapy Landscape in 2026: What International Patients Need to Know2026年中国基因编辑与干细胞治疗格局:国际患者需要了解什么

China has become one of the world’s busiest hubs for cell and gene therapy research. From CAR-T treatments for blood cancers to base-editing programs targeting inherited blood disorders, the country’s clinical pipeline has expanded fast. Bu…China has become one of the world’s busiest hubs for cell and gene therapy research. From CAR-T treatments for blood cancers to base-editing programs targeting inherited blood disorders, the country’s clinical pipeline has expanded fast. Bu…中国已成为全球细胞与基因治疗研究最活跃的中心之一。从针对血液肿瘤的 CAR-T 治疗,到瞄准遗传性血液疾病的碱基编辑项目,中国的临床管线扩展迅速。但对于正在考虑赴华治疗的国际患者而言,有一个区别比其他任何因素都更重要:某种疗法究竟是已商业化可用、只能通过正式临床试验获得,还是仍处于早期实验阶段。

China has become one of the world’s busiest hubs for cell and gene therapy research. From CAR-T treatments for blood cancers to base-editing programs targeting inherited blood disorders, the country’s clinical pipeline has expanded fast. But for international patients looking at treatment options in China, one distinction matters more than anything else: whether a therapy is commercially available, only accessible through a formal clinical trial, or still in an early experimental phase.

Here’s a grounded look at the current landscape, based on verified clinical data, regulatory frameworks, and hospital capabilities as of mid-2026.

Gene Editing and Stem Cell Therapy Are Not the Same Thing

These two fields are closely linked, but they solve different problems.

Gene editing uses tools such as CRISPR-Cas9 or base editing to modify a patient’s DNA and correct disease-causing mutations. Stem cell therapy, by contrast, relies on regenerative cells to repair or replace damaged tissue. In some of the most advanced programs, the two approaches are combined: doctors collect a patient’s own stem cells, edit them in a lab, and then reinfuse them to treat a genetic disorder.

Ex vivo vs. in vivo

Most current therapies in China follow an ex vivo model. Cells are removed from the patient, edited in a specialized facility, and then returned after the patient undergoes conditioning chemotherapy. That’s the standard approach in therapies for β-thalassemia and sickle cell disease.

An in vivo model is also starting to enter clinical trials. Instead of removing cells, doctors deliver gene-editing tools directly into the body through intravenous infusion. That could eventually eliminate the need for cell extraction and chemotherapy conditioning, potentially making treatment safer and easier to access.

Base editing vs. traditional CRISPR

Traditional CRISPR-Cas9 cuts both strands of DNA, which can introduce risks such as chromosomal rearrangements or large deletions. Base editing, a newer approach developed by Chinese research teams, changes individual DNA letters without cutting the double helix. That added precision may reduce off-target effects, and early clinical data has been encouraging.

Where the Technology Is Furthest Along

β-Thalassemia and sickle cell disease

The most advanced gene-editing stem cell work in China is aimed at transfusion-dependent β-thalassemia (TDT), a severe inherited blood disorder that typically requires lifelong transfusions.

CS-101

CS-101, developed by CorrectSequence Therapeutics in collaboration with ShanghaiTech University and the First Affiliated Hospital of Guangxi Medical University, uses a "transformer base editor" (tBE) to reactivate fetal hemoglobin production in a patient’s own blood stem cells.

In a Phase 1 trial published in Nature in 2026, five patients achieved transfusion independence within a median of 18 days after infusion. Over a median follow-up of 23 months, all patients maintained stable hemoglobin levels without needing red blood cell transfusions, and no off-target edits or therapy-related serious adverse events were reported. The first treated patient has remained transfusion-free for more than 28 months.

As of mid-2026, CS-101 has completed Phase 1 trials and has been used to treat about 20 patients with β-thalassemia or sickle cell disease, including international patients from Laos and Pakistan. Phase 2/3 trials are now underway.

BRL-101

BRL-101, developed by Boyang Bio and tested at Xiangya Hospital, uses CRISPR-Cas9 to edit the BCL11A enhancer region in patient stem cells. In an early clinical trial, six pediatric patients — including four with the severe β0/β0 genotype — achieved transfusion independence after treatment.

The headline here is significant, but it also comes with an important caveat: these programs remain in clinical development. Transfusion independence is a major milestone, but long-term durability and safety still need further follow-up.

Blood cancers

This is the area where China already has fully commercialized cell therapy.

Unlike gene-editing treatments for inherited diseases, CAR-T therapy for blood cancers is commercially available in China. As of July 2026, the National Medical Products Administration (NMPA) has approved nine CAR-T products covering lymphoma, leukemia, multiple myeloma, and, notably, gastric cancer. That last approval is particularly notable because satri-cel, approved in June 2026, became the world’s first approved solid-tumor CAR-T.

These approved products are delivered at designated tertiary hospitals. Treatment costs typically range from about $120,000 to $215,000 USD, which is still substantially lower than comparable therapies in many Western markets. International patients can access them through standard clinical pathways, though that generally requires a medical visa and a pre-treatment evaluation.

Parkinson’s disease

Shanghai East Hospital, affiliated with Tongji University, has launched China’s first clinical trial using induced pluripotent stem cells (iPSCs) for Parkinson’s disease.

The treatment involves reprogramming a patient’s own cells into stem cells, differentiating them into dopamine-producing neurons, and transplanting those cells into the brain. Twelve-month results announced in early 2025 showed improvements in motor function and quality of life among participants.

Still, this remains an early-phase investigator-initiated trial rather than an approved therapy. More data is needed before anyone can draw conclusions about long-term safety or effectiveness.

Diabetes

In Hainan Province, the Boao Lecheng International Medical Tourism Pilot Zone offers regulated access to mesenchymal stem cell (MSC) therapy for Type 2 diabetes.

These therapies use allogeneic umbilical cord-derived stem cells to modulate inflammation and support pancreatic beta-cell function. This is not gene-editing therapy. It is a regenerative medicine approach offered under special-zone rules.

Published studies suggest that some patients reduce medication needs or improve glycemic control, but outcomes vary, and durability beyond 3–5 years has not been established. Treatment typically costs between $15,000 and $35,000 USD.

The Hospitals Driving This Work

A relatively small group of top-tier institutions is doing much of the serious clinical work in this space.

First Affiliated Hospital of Guangxi Medical University, Nanning

This hospital is a national center for thalassemia treatment, with more than 1,200 bone marrow transplants performed. It is also the lead clinical site for CS-101 base-editing trials and has extensive experience in hematopoietic stem cell transplantation for genetic blood disorders.

Peking University People’s Hospital, Beijing

One of China’s leading centers for hematology and CAR-T therapy, with deep expertise in leukemia, lymphoma, and bone marrow transplantation.

Ruijin Hospital / Shanghai Jiao Tong University School of Medicine, Shanghai

A major center for blood diseases and CAR-T therapy. Its Hainan Boao campus, Ruijin Hainan Hospital, also offers stem cell therapies within the special medical tourism zone.

Shanghai East Hospital, Shanghai

Affiliated with Tongji University, this hospital is conducting early-phase iPSC trials for Parkinson’s disease and other neurological disorders.

Children’s Hospital of Fudan University, Shanghai

A national pediatric medical center with a dedicated rare-disease research ward. It has treated international patients with severe β-thalassemia using CS-101 base-editing therapy and runs trials for spinal muscular atrophy, Fabry disease, and other rare genetic conditions.

West China Hospital, Sichuan University, Chengdu

In 2016, this hospital carried out the world’s first human clinical trial of CRISPR-edited T-cells for advanced lung cancer. It remains active in gene-editing and immuno-oncology research.

Chinese Academy of Medical Sciences Blood Disease Hospital, Tianjin

A specialized national hematology center with strong programs in stem cell transplantation and blood cancer treatment.

The Big Regulatory Shift: Order 818

A major policy change landed on May 1, 2026, when China’s State Council Order No. 818 — officially titled the Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies — took effect.

This is China’s first national administrative regulation specifically focused on cell therapy, gene editing, and other advanced biomedical technologies.

What it means for patients

  • A dual-track system: Therapies can now move through either the traditional NMPA drug registration route for broad commercial products, or a "technology translation" pathway that lets qualified Grade 3A hospitals offer certain personalized therapies after clinical research and ethics review.
  • Hospital-only access: Clinical translation is limited to top-tier tertiary hospitals with accredited ethics committees and specialized facilities.
  • No charging during research: Patients cannot be charged for the experimental therapy itself during clinical trials or investigator-initiated trials. Costs may only apply after a therapy receives clinical translation approval.
  • Stronger enforcement: Unauthorized use of unproven therapies now carries heavy fines, reinforcing the need to stick with legitimate institutions.

The goal is clear: speed up access to genuine breakthroughs while shutting down the kind of loosely regulated stem cell clinics that operated in gray areas for years.

What International Patients Should Actually Watch For

The most important takeaway is also the simplest one: most gene-editing stem cell therapies in China are still not commercially approved.

Outside of CAR-T and some stem cell products in Hainan Boao, most gene-editing options remain trial-based. That means access is usually tied to enrollment criteria, not direct consumer choice.

Don’t confuse “transfusion independence” with “cure”

The early thalassemia results are genuinely promising. But data beyond 2–3 years is still limited. For now, these therapies are best understood as potentially curative, not definitively proven cures.

Avoid unregulated clinics

Even with tighter oversight, some private clinics may still market unproven stem cell interventions for anti-aging, diabetes, or neurological diseases without proper trial registration. Any patient considering treatment should verify that it is being offered through a Grade 3A public hospital with ethics approval and a legitimate clinical trial registration, including listings on ClinicalTrials.gov or the China Clinical Trial Registry.

Costs and logistics

Here’s the practical cost picture based on currently available options:

  • Commercial CAR-T: $120,000–$215,000 USD
  • MSC stem cell therapy in Boao Lecheng: $15,000–$35,000 USD
  • Clinical trial therapies: often no treatment cost, though travel, accommodation, and pre-treatment workup still apply

Medical visas, typically the S2 category, require official invitation letters from the hospital.

Language and care coordination

Major hospitals in Beijing, Shanghai, and other top-tier cities increasingly have international departments and some English-speaking staff. But in practice, navigating consultations, translating records, and coordinating follow-up care often requires professional support.

The Bottom Line

China’s gene-editing and stem cell sector has moved well beyond basic research and into real clinical innovation. The clearest example is β-thalassemia, where base-editing programs have already produced internationally recognized results. At the same time, the regulatory picture has become more structured under Order 818, creating clearer channels for legitimate therapies while making it harder for unproven operators to function.

For international patients, expectations need to stay aligned with reality. CAR-T is commercially available and established. Gene-editing treatments for inherited blood disorders are in advanced clinical trials with strong early data. Most other applications — including Parkinson’s disease, diabetes, and anti-aging — either remain experimental or rely on conventional stem cell approaches rather than gene editing.

The safest path is straightforward: contact the international departments at major tertiary hospitals, confirm whether your condition matches an approved indication or an open clinical trial, and make sure any treatment is delivered under proper regulatory oversight.

This article is intended for informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals. Clinical trial availability and eligibility criteria can change frequently, so patients should verify current status directly with hospitals or official registries.

China has become one of the world’s busiest hubs for cell and gene therapy research. From CAR-T treatments for blood cancers to base-editing programs targeting inherited blood disorders, the country’s clinical pipeline has expanded fast. But for international patients looking at treatment options in China, one distinction matters more than anything else: whether a therapy is commercially available, only accessible through a formal clinical trial, or still in an early experimental phase.

Here’s a grounded look at the current landscape, based on verified clinical data, regulatory frameworks, and hospital capabilities as of mid-2026.

Gene Editing and Stem Cell Therapy Are Not the Same Thing

These two fields are closely linked, but they solve different problems.

Gene editing uses tools such as CRISPR-Cas9 or base editing to modify a patient’s DNA and correct disease-causing mutations. Stem cell therapy, by contrast, relies on regenerative cells to repair or replace damaged tissue. In some of the most advanced programs, the two approaches are combined: doctors collect a patient’s own stem cells, edit them in a lab, and then reinfuse them to treat a genetic disorder.

Ex vivo vs. in vivo

Most current therapies in China follow an ex vivo model. Cells are removed from the patient, edited in a specialized facility, and then returned after the patient undergoes conditioning chemotherapy. That’s the standard approach in therapies for β-thalassemia and sickle cell disease.

An in vivo model is also starting to enter clinical trials. Instead of removing cells, doctors deliver gene-editing tools directly into the body through intravenous infusion. That could eventually eliminate the need for cell extraction and chemotherapy conditioning, potentially making treatment safer and easier to access.

Base editing vs. traditional CRISPR

Traditional CRISPR-Cas9 cuts both strands of DNA, which can introduce risks such as chromosomal rearrangements or large deletions. Base editing, a newer approach developed by Chinese research teams, changes individual DNA letters without cutting the double helix. That added precision may reduce off-target effects, and early clinical data has been encouraging.

Where the Technology Is Furthest Along

β-Thalassemia and sickle cell disease

The most advanced gene-editing stem cell work in China is aimed at transfusion-dependent β-thalassemia (TDT), a severe inherited blood disorder that typically requires lifelong transfusions.

CS-101

CS-101, developed by CorrectSequence Therapeutics in collaboration with ShanghaiTech University and the First Affiliated Hospital of Guangxi Medical University, uses a "transformer base editor" (tBE) to reactivate fetal hemoglobin production in a patient’s own blood stem cells.

In a Phase 1 trial published in Nature in 2026, five patients achieved transfusion independence within a median of 18 days after infusion. Over a median follow-up of 23 months, all patients maintained stable hemoglobin levels without needing red blood cell transfusions, and no off-target edits or therapy-related serious adverse events were reported. The first treated patient has remained transfusion-free for more than 28 months.

As of mid-2026, CS-101 has completed Phase 1 trials and has been used to treat about 20 patients with β-thalassemia or sickle cell disease, including international patients from Laos and Pakistan. Phase 2/3 trials are now underway.

BRL-101

BRL-101, developed by Boyang Bio and tested at Xiangya Hospital, uses CRISPR-Cas9 to edit the BCL11A enhancer region in patient stem cells. In an early clinical trial, six pediatric patients — including four with the severe β0/β0 genotype — achieved transfusion independence after treatment.

The headline here is significant, but it also comes with an important caveat: these programs remain in clinical development. Transfusion independence is a major milestone, but long-term durability and safety still need further follow-up.

Blood cancers

This is the area where China already has fully commercialized cell therapy.

Unlike gene-editing treatments for inherited diseases, CAR-T therapy for blood cancers is commercially available in China. As of July 2026, the National Medical Products Administration (NMPA) has approved nine CAR-T products covering lymphoma, leukemia, multiple myeloma, and, notably, gastric cancer. That last approval is particularly notable because satri-cel, approved in June 2026, became the world’s first approved solid-tumor CAR-T.

These approved products are delivered at designated tertiary hospitals. Treatment costs typically range from about $120,000 to $215,000 USD, which is still substantially lower than comparable therapies in many Western markets. International patients can access them through standard clinical pathways, though that generally requires a medical visa and a pre-treatment evaluation.

Parkinson’s disease

Shanghai East Hospital, affiliated with Tongji University, has launched China’s first clinical trial using induced pluripotent stem cells (iPSCs) for Parkinson’s disease.

The treatment involves reprogramming a patient’s own cells into stem cells, differentiating them into dopamine-producing neurons, and transplanting those cells into the brain. Twelve-month results announced in early 2025 showed improvements in motor function and quality of life among participants.

Still, this remains an early-phase investigator-initiated trial rather than an approved therapy. More data is needed before anyone can draw conclusions about long-term safety or effectiveness.

Diabetes

In Hainan Province, the Boao Lecheng International Medical Tourism Pilot Zone offers regulated access to mesenchymal stem cell (MSC) therapy for Type 2 diabetes.

These therapies use allogeneic umbilical cord-derived stem cells to modulate inflammation and support pancreatic beta-cell function. This is not gene-editing therapy. It is a regenerative medicine approach offered under special-zone rules.

Published studies suggest that some patients reduce medication needs or improve glycemic control, but outcomes vary, and durability beyond 3–5 years has not been established. Treatment typically costs between $15,000 and $35,000 USD.

The Hospitals Driving This Work

A relatively small group of top-tier institutions is doing much of the serious clinical work in this space.

First Affiliated Hospital of Guangxi Medical University, Nanning

This hospital is a national center for thalassemia treatment, with more than 1,200 bone marrow transplants performed. It is also the lead clinical site for CS-101 base-editing trials and has extensive experience in hematopoietic stem cell transplantation for genetic blood disorders.

Peking University People’s Hospital, Beijing

One of China’s leading centers for hematology and CAR-T therapy, with deep expertise in leukemia, lymphoma, and bone marrow transplantation.

Ruijin Hospital / Shanghai Jiao Tong University School of Medicine, Shanghai

A major center for blood diseases and CAR-T therapy. Its Hainan Boao campus, Ruijin Hainan Hospital, also offers stem cell therapies within the special medical tourism zone.

Shanghai East Hospital, Shanghai

Affiliated with Tongji University, this hospital is conducting early-phase iPSC trials for Parkinson’s disease and other neurological disorders.

Children’s Hospital of Fudan University, Shanghai

A national pediatric medical center with a dedicated rare-disease research ward. It has treated international patients with severe β-thalassemia using CS-101 base-editing therapy and runs trials for spinal muscular atrophy, Fabry disease, and other rare genetic conditions.

West China Hospital, Sichuan University, Chengdu

In 2016, this hospital carried out the world’s first human clinical trial of CRISPR-edited T-cells for advanced lung cancer. It remains active in gene-editing and immuno-oncology research.

Chinese Academy of Medical Sciences Blood Disease Hospital, Tianjin

A specialized national hematology center with strong programs in stem cell transplantation and blood cancer treatment.

The Big Regulatory Shift: Order 818

A major policy change landed on May 1, 2026, when China’s State Council Order No. 818 — officially titled the Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies — took effect.

This is China’s first national administrative regulation specifically focused on cell therapy, gene editing, and other advanced biomedical technologies.

What it means for patients

  • A dual-track system: Therapies can now move through either the traditional NMPA drug registration route for broad commercial products, or a "technology translation" pathway that lets qualified Grade 3A hospitals offer certain personalized therapies after clinical research and ethics review.
  • Hospital-only access: Clinical translation is limited to top-tier tertiary hospitals with accredited ethics committees and specialized facilities.
  • No charging during research: Patients cannot be charged for the experimental therapy itself during clinical trials or investigator-initiated trials. Costs may only apply after a therapy receives clinical translation approval.
  • Stronger enforcement: Unauthorized use of unproven therapies now carries heavy fines, reinforcing the need to stick with legitimate institutions.

The goal is clear: speed up access to genuine breakthroughs while shutting down the kind of loosely regulated stem cell clinics that operated in gray areas for years.

What International Patients Should Actually Watch For

The most important takeaway is also the simplest one: most gene-editing stem cell therapies in China are still not commercially approved.

Outside of CAR-T and some stem cell products in Hainan Boao, most gene-editing options remain trial-based. That means access is usually tied to enrollment criteria, not direct consumer choice.

Don’t confuse “transfusion independence” with “cure”

The early thalassemia results are genuinely promising. But data beyond 2–3 years is still limited. For now, these therapies are best understood as potentially curative, not definitively proven cures.

Avoid unregulated clinics

Even with tighter oversight, some private clinics may still market unproven stem cell interventions for anti-aging, diabetes, or neurological diseases without proper trial registration. Any patient considering treatment should verify that it is being offered through a Grade 3A public hospital with ethics approval and a legitimate clinical trial registration, including listings on ClinicalTrials.gov or the China Clinical Trial Registry.

Costs and logistics

Here’s the practical cost picture based on currently available options:

  • Commercial CAR-T: $120,000–$215,000 USD
  • MSC stem cell therapy in Boao Lecheng: $15,000–$35,000 USD
  • Clinical trial therapies: often no treatment cost, though travel, accommodation, and pre-treatment workup still apply

Medical visas, typically the S2 category, require official invitation letters from the hospital.

Language and care coordination

Major hospitals in Beijing, Shanghai, and other top-tier cities increasingly have international departments and some English-speaking staff. But in practice, navigating consultations, translating records, and coordinating follow-up care often requires professional support.

The Bottom Line

China’s gene-editing and stem cell sector has moved well beyond basic research and into real clinical innovation. The clearest example is β-thalassemia, where base-editing programs have already produced internationally recognized results. At the same time, the regulatory picture has become more structured under Order 818, creating clearer channels for legitimate therapies while making it harder for unproven operators to function.

For international patients, expectations need to stay aligned with reality. CAR-T is commercially available and established. Gene-editing treatments for inherited blood disorders are in advanced clinical trials with strong early data. Most other applications — including Parkinson’s disease, diabetes, and anti-aging — either remain experimental or rely on conventional stem cell approaches rather than gene editing.

The safest path is straightforward: contact the international departments at major tertiary hospitals, confirm whether your condition matches an approved indication or an open clinical trial, and make sure any treatment is delivered under proper regulatory oversight.

This article is intended for informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals. Clinical trial availability and eligibility criteria can change frequently, so patients should verify current status directly with hospitals or official registries.

中国已成为全球细胞与基因治疗研究最活跃的中心之一。从针对血液肿瘤的 CAR-T 治疗,到瞄准遗传性血液疾病的碱基编辑项目,中国的临床管线扩展迅速。但对于正在考虑赴华治疗的国际患者而言,有一个区别比其他任何因素都更重要:某种疗法究竟是已商业化可用、只能通过正式临床试验获得,还是仍处于早期实验阶段。

以下基于截至 2026 年年中的已核实临床数据、监管框架和医院能力,对当前格局作出务实梳理。

基因编辑和干细胞治疗并不是一回事

这两个领域关系密切,但解决的是不同问题。

基因编辑使用 CRISPR-Cas9 或碱基编辑等工具来修改患者 DNA,纠正致病突变。相比之下,干细胞治疗依赖再生细胞来修复或替代受损组织。在一些最先进的项目中,这两种方法会结合使用:医生采集患者自身的干细胞,在实验室中进行编辑,然后再回输以治疗遗传性疾病。

Ex vivo 与 in vivo

中国当前的大多数疗法采用 ex vivo 模式。细胞先从患者体内取出,在专业设施中完成编辑,然后在患者接受预处理化疗后回输体内。这是 β-地中海贫血和镰状细胞病治疗中的标准做法。

in vivo 模式也开始进入临床试验。医生不是取出细胞,而是通过静脉输注将基因编辑工具直接送入体内。最终,这可能免除细胞提取和化疗预处理的需要,从而有望使治疗更安全、更易获得。

碱基编辑 vs. 传统 CRISPR

传统 CRISPR-Cas9 会切断 DNA 的双链,这可能带来染色体重排或大片段缺失等风险。碱基编辑是中国科研团队推进的一种较新方法,它无需切断双螺旋即可改变单个 DNA 字母。这种更高的精确性可能降低脱靶效应,早期临床数据也令人鼓舞。

哪些技术进展最领先

β-地中海贫血和镰状细胞病

中国最先进的基因编辑干细胞研究主要针对输血依赖型 β-地中海贫血(TDT),这是一种严重的遗传性血液疾病,通常需要终身输血。

CS-101

CS-101 由 CorrectSequence Therapeutics 与上海科技大学、广西医科大学第一附属医院合作开发,采用“transformer base editor”(tBE)在患者自身造血干细胞中重新激活胎儿血红蛋白的产生。

在 2026 年发表于 Nature 的一项 1 期试验中,5 名患者在输注后中位 18 天内实现输血脱离。在中位 23 个月的随访期间,所有患者均维持稳定的血红蛋白水平,无需红细胞输血,且未报告脱靶编辑或与治疗相关的严重不良事件。首位接受治疗的患者已持续超过 28 个月无需输血。

截至 2026 年年中,CS-101 已完成 1 期试验,并已用于治疗约 20 名 β-地中海贫血或镰状细胞病患者,其中包括来自老挝和巴基斯坦的国际患者。2/3 期试验目前正在进行中。

BRL-101

BRL-101 由博雅生物开发,并在湘雅医院开展测试,使用 CRISPR-Cas9 编辑患者干细胞中的 BCL11A 增强子区域。在一项早期临床试验中,6 名儿科患者——其中包括 4 名严重 β0/β0 基因型患者——在治疗后实现了输血脱离。

这一结果意义重大,但也伴随着一个重要前提:这些项目仍处于临床开发阶段。输血脱离是一个重要里程碑,但其长期持久性和安全性仍需要进一步随访。

血液肿瘤

这是中国已经拥有完全商业化细胞治疗的领域。

不同于针对遗传病的基因编辑疗法,血液肿瘤的 CAR-T 治疗在中国已可商业获得。截至 2026 年 7 月,国家药品监督管理局(NMPA)已批准 9 款 CAR-T 产品,覆盖淋巴瘤、白血病、多发性骨髓瘤,以及值得特别注意的胃癌。最后这一项批准尤为引人注目,因为 satri-cel 于 2026 年 6 月获批,成为全球首个获批的实体瘤 CAR-T。

这些获批产品由指定的三级医院提供。治疗费用通常约为 120,000 至 215,000 美元,仍明显低于许多西方市场中的同类疗法。国际患者可通过标准临床路径获得治疗,但通常需要医疗签证和治疗前评估。

帕金森病

同济大学附属上海市东方医院已启动中国首项使用诱导多能干细胞(iPSC)治疗帕金森病的临床试验。

该治疗方案包括将患者自身细胞重编程为干细胞,将其诱导分化为产生多巴胺的神经元,并将这些细胞移植入脑内。2025 年初公布的 12 个月结果显示,参与者的运动功能和生活质量均有所改善。

不过,这仍是一项研究者发起的早期试验,而非已获批准的疗法。在对长期安全性或有效性作出结论之前,仍需要更多数据。

糖尿病

在海南省,博鳌乐城国际医疗旅游先行区提供对 2 型糖尿病间充质干细胞(MSC)治疗的合规准入。

这些疗法使用异体脐带来源干细胞来调节炎症并支持胰岛 β 细胞功能。这不是基因编辑疗法,而是在特殊区域规则下提供的一种再生医学方案。

已发表研究提示,部分患者可减少用药需求或改善血糖控制,但结果存在差异,而且 3–5 年以上的持久性尚未确立。治疗费用通常在 15,000 至 35,000 美元之间。

推动这项工作的医院

真正开展这类严肃临床工作的,主要是少数几家顶级机构。

广西医科大学第一附属医院,南宁

这家医院是国家级地中海贫血诊疗中心,已开展超过 1,200 例骨髓移植。它也是 CS-101 碱基编辑试验的主要临床中心,并在遗传性血液疾病的造血干细胞移植方面拥有丰富经验。

北京大学人民医院,北京

中国血液学和 CAR-T 治疗领先中心之一,在白血病、淋巴瘤和骨髓移植方面具有深厚专长。

瑞金医院 / 上海交通大学医学院,上海

血液疾病和 CAR-T 治疗的重要中心。其海南博鳌院区——瑞金海南医院——也在特殊医疗旅游区域内提供干细胞治疗。

上海市东方医院,上海

隶属于同济大学,这家医院正在开展针对帕金森病和其他神经系统疾病的 iPSC 早期试验。

复旦大学附属儿科医院,上海

国家儿童医学中心,设有专门的罕见病研究病房。该院已使用 CS-101 碱基编辑疗法治疗重型 β-地中海贫血国际患者,并开展脊髓性肌萎缩症、法布里病及其他罕见遗传病的试验。

四川大学华西医院,成都

2016 年,该院开展了全球首项针对晚期肺癌的 CRISPR 编辑 T 细胞人体临床试验。其目前仍活跃于基因编辑和肿瘤免疫研究。

中国医学科学院血液病医院,天津

国家级专业血液学中心,在干细胞移植和血液肿瘤治疗方面实力强劲。

重大监管转变:818 号令

2026 年 5 月 1 日,中国国务院第 818 号令正式生效,带来一项重大政策变化。该法规全称为 Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies。

这是中国首部专门聚焦细胞治疗、基因编辑及其他先进生物医学技术的国家行政法规。

这对患者意味着什么

  • 双轨制体系: 疗法现在可通过传统的 NMPA 药品注册路径进入广泛商业化,也可通过“技术转化”路径,在完成临床研究和伦理审查后,由符合条件的三级甲等医院提供某些个体化疗法。
  • 仅限医院提供: 临床转化仅限于具备认证伦理委员会和专业设施的顶级三级医院。
  • 研究期间不得收费: 在临床试验或研究者发起试验期间,不得就实验性疗法本身向患者收费。只有在疗法获得临床转化批准后,才可能产生相关费用。
  • 更强执法: 未经授权使用未经证实的疗法如今将面临高额罚款,这进一步强调了必须选择正规机构。

目标很明确:加快真正突破性疗法的可及性,同时关闭那些多年来在灰色地带运作、监管宽松的干细胞诊所。

国际患者真正应该关注什么

最重要的结论也是最简单的一点:中国大多数基因编辑干细胞疗法仍未获得商业批准。

除 CAR-T 和海南博鳌的部分干细胞产品外,大多数基因编辑选项仍以试验为基础。这意味着获得治疗通常取决于入组标准,而不是患者直接消费选择。

不要把“输血脱离”等同于“治愈”

早期地中海贫血结果确实很有前景。但超过 2–3 年的数据仍然有限。目前,这些疗法更适合被理解为具有潜在治愈性,而不是已被明确证实的治愈方案。

避开不受监管的诊所

即使监管趋严,一些私立诊所仍可能在未进行适当试验注册的情况下,推广用于抗衰老、糖尿病或神经系统疾病的未经证实干细胞干预。任何考虑接受治疗的患者都应核实,该治疗是否由具有伦理批准和合法临床试验注册的三级甲等公立医院提供,包括在 ClinicalTrials.gov 或中国临床试验注册中心上的登记。

费用与流程安排

基于当前可获得的选项,实际费用大致如下:

  • 商业化 CAR-T:120,000–215,000 美元
  • 博鳌乐城 MSC 干细胞治疗:15,000–35,000 美元
  • 临床试验疗法:通常无需治疗费用,但仍需承担旅行、住宿和治疗前检查费用

医疗签证通常为 S2 类别,需要医院出具正式邀请函。

语言与照护协调

北京、上海及其他一线城市的大型医院越来越多地设有国际部,也有部分会说英语的工作人员。但在实际操作中,咨询就诊、病历翻译和后续照护协调往往仍需要专业支持。

总结

中国的基因编辑和干细胞领域早已超越基础研究,进入真正的临床创新阶段。最明显的例子是 β-地中海贫血,相关碱基编辑项目已经取得国际认可的成果。与此同时,随着 818 号令实施,监管图景也变得更加规范,为合法疗法建立了更清晰的通道,同时也让未经证实的经营者更难运作。

对于国际患者而言,预期需要与现实保持一致。CAR-T 已经商业化应用并且相对成熟。针对遗传性血液疾病的基因编辑疗法已进入后期临床试验阶段,且早期数据表现强劲。其他大多数应用——包括帕金森病、糖尿病和抗衰老——要么仍处于实验阶段,要么依赖传统干细胞方法而非基因编辑。

最安全的路径其实很明确:联系大型三级医院的国际部,确认您的病情是否符合已获批适应证或正在开放的临床试验,并确保任何治疗都在适当的监管监督下进行。

本文仅供参考,不构成医疗建议。治疗决策始终应在合格医疗专业人员的咨询指导下作出。临床试验的可及性和入组标准可能经常变化,因此患者应直接向医院或官方注册平台核实当前状态。

WhatsApp